JPMorgan Chase & Co. Makes New $83,000 Investment in Rapport Therapeutics (NASDAQ:RAPP)

JPMorgan Chase & Co. purchased a new stake in Rapport Therapeutics (NASDAQ:RAPP) in the third quarter, Holdings Channel reports. The institutional investor purchased 4,033 shares of the company’s stock, valued at approximately $83,000.

Several other large investors have also bought and sold shares of the stock. Charles Schwab Investment Management Inc. acquired a new stake in shares of Rapport Therapeutics in the 3rd quarter valued at about $1,498,000. Millennium Management LLC bought a new position in shares of Rapport Therapeutics in the second quarter worth $2,716,000. Geode Capital Management LLC purchased a new stake in Rapport Therapeutics during the third quarter valued at about $4,133,000. State Street Corp purchased a new stake in Rapport Therapeutics during the third quarter valued at about $1,189,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Rapport Therapeutics during the second quarter worth about $1,757,000.

Rapport Therapeutics Stock Up 1.2 %

Shares of NASDAQ RAPP opened at $16.60 on Tuesday. The company has a 50 day simple moving average of $17.78 and a two-hundred day simple moving average of $20.45. Rapport Therapeutics has a fifty-two week low of $12.09 and a fifty-two week high of $29.74.

Rapport Therapeutics (NASDAQ:RAPP) last released its earnings results on Thursday, November 7th. The company reported ($0.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.07. Analysts predict that Rapport Therapeutics will post -3.65 earnings per share for the current fiscal year.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.